Farallon Capital Management, L.L.C. and 13 associated individuals filed a Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 3,974,000 shares of Avalo Therapeutics, Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Farallon Capital Management, L.L.C. and each named individual report 3,974,000 shares of Avalo Therapeutics common stock beneficially owned.
  • Percent of class: The 3,974,000 shares represent 7.4% of the class, according to the filing.
  • Shared voting and dispositive power: All reporting persons report 0 sole voting power and 0 sole dispositive power; all 3,974,000 shares are held with shared voting and shared dispositive power.
  • Triggering event date: The date of the event requiring the filing is listed as September 30, 2026.
  • Security covered: Common Stock, par value $0.001 per share, CUSIP 05338F306.
  • Reporting entity type: Farallon Capital Management, L.L.C. is classified as IA (Investment Adviser) and OO; the 13 individual reporting persons are each classified as HC (Holding Company) and IN (Individual).

Farallon Capital and Associates Disclose 3,974,000 Shares in Avalo Therapeutics

According to the Schedule 13G filed November 13, 2026, Farallon Capital Management, L.L.C., a Delaware-organized entity, together with 13 individually named persons, reported aggregate beneficial ownership of 3,974,000 shares of Avalo Therapeutics, Inc. common stock. The filing lists the par value of the covered security as $0.001 per share and identifies the CUSIP number as 05338F306. The event triggering the filing occurred on September 30, 2026.

The filing discloses that none of the reporting persons hold sole voting or sole dispositive power over any of the 3,974,000 shares. Instead, all voting and dispositive power is reported as shared among the reporting persons. Each of the 13 individuals named in the filing - including Joshua J. Dapice, Philip D. Dreyfuss, Hannah E. Dunn, Varun N. Gehani, Nicolas Giauque, Avner A. Husen, David T. Kim, Michael G. Linn, Patrick (Cheng) Luo, Thomas G. Roberts Jr., Edric C. Saito, Daniel S. Short, and Andrew J. M. Spokes - separately reports the same 3,974,000 shares and the same 7.4% ownership percentage as Farallon Capital Management, L.L.C.

Farallon Capital Management, L.L.C. is classified in the filing as type IA and OO, while each individual reporting person is classified as HC and IN. The filing does not specify the acquisition price or the specific transactions underlying the reported position. No ticker symbol for Avalo Therapeutics appears on the face of this Schedule 13G filing.

What Was Disclosed

Farallon Capital Management, L.L.C. and 13 named individuals filed a Schedule 13G disclosing shared beneficial ownership of 3,974,000 shares, equal to 7.4% of Avalo Therapeutics, Inc. common stock, as of September 30, 2026.